These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20691740)

  • 1. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
    Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
    J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
    Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
    Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
    Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
    J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms.
    Reddy LH; Ferreira H; Dubernet C; Mouelhi SL; Desmaele D; Rousseau B; Couvreur P
    Anticancer Drugs; 2008 Nov; 19(10):999-1006. PubMed ID: 18827565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.
    Reddy LH; Khoury H; Paci A; Deroussent A; Ferreira H; Dubernet C; Declèves X; Besnard M; Chacun H; Lepêtre-Mouelhi S; Desmaële D; Rousseau B; Laugier C; Cintrat JC; Vassal G; Couvreur P
    Drug Metab Dispos; 2008 Aug; 36(8):1570-7. PubMed ID: 18474674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
    Arias JL; Reddy LH; Couvreur P
    Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
    Valetti S; Maione F; Mura S; Stella B; Desmaële D; Noiray M; Vergnaud J; Vauthier C; Cattel L; Giraudo E; Couvreur P
    J Control Release; 2014 Oct; 192():29-39. PubMed ID: 24984010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
    Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
    Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
    Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
    Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer.
    Neutsch L; Wirth EM; Spijker S; Pichl C; Kählig H; Gabor F; Wirth M
    J Control Release; 2013 Jul; 169(1-2):62-72. PubMed ID: 23588390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies.
    Bekkara-Aounallah F; Ambike A; Gref R; Couvreur P; Rosilio V
    Int J Pharm; 2014 Aug; 471(1-2):75-82. PubMed ID: 24811925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System.
    Dong S; He J; Sun Y; Li D; Li L; Zhang M; Ni P
    Mol Pharm; 2019 Sep; 16(9):3770-3779. PubMed ID: 31348660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.
    Gaudin A; Song E; King AR; Saucier-Sawyer JK; Bindra R; Desmaële D; Couvreur P; Saltzman WM
    Biomaterials; 2016 Oct; 105():136-144. PubMed ID: 27521616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermosensitive polymer prodrug nanoparticles prepared by an all-aqueous nanoprecipitation process and application to combination therapy.
    Guerassimoff L; Ferrere M; Van Herck S; Dehissi S; Nicolas V; De Geest BG; Nicolas J
    J Control Release; 2024 May; 369():376-393. PubMed ID: 38554772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Freeze-drying of squalenoylated nucleoside analogue nanoparticles.
    Bildstein L; Hillaireau H; Desmaële D; Lepêtre-Mouelhi S; Dubernet C; Couvreur P
    Int J Pharm; 2009 Nov; 381(2):140-5. PubMed ID: 19782881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
    Wu W; Sigmond J; Peters GJ; Borch RF
    J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
    Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
    J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
    Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
    Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
    Mura S; Buchy E; Askin G; Cayre F; Mougin J; Gouazou S; Sobot D; Valetti S; Stella B; Desmaele D; Couvreur P
    Biochimie; 2016 Nov; 130():4-13. PubMed ID: 27519301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.